Morabito Quoted in The Wall Street Journal about Court Approval of GST AutoLeather Bankruptcy Sale
November 13, 2017
Wall Street Journal
Partner Erika Morabito is quoted in a Wall Street Journal article, “GST AutoLeather Wins Court Approval of Bankruptcy Sale Process,” about an agreement between the company’s lenders and unsecured creditors on financing, fees and a process to sell the bankrupt upholstery maker’s business.
Morabito, counsel to the company’s official committee of unsecured creditors, said during a bankruptcy hearing that the lenders were holding the process “hostage” and called “insulting” a court filing by Royal Bank of Canada, part of a group of lenders, that said the unsecured creditors “should be cheering” the financing, “not objecting” to it.
Click here to read the full article (subscription required).
Morabito, counsel to the company’s official committee of unsecured creditors, said during a bankruptcy hearing that the lenders were holding the process “hostage” and called “insulting” a court filing by Royal Bank of Canada, part of a group of lenders, that said the unsecured creditors “should be cheering” the financing, “not objecting” to it.
Click here to read the full article (subscription required).
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."